Alnylam Pharmaceuticals’ (ALNY) “Sell (D-)” Rating Reiterated at Weiss Ratings

Weiss Ratings reissued their sell (d-) rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research note released on Wednesday morning,Weiss Ratings reports.

Other equities analysts have also issued research reports about the company. Canaccord Genuity Group lifted their price target on Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Barclays boosted their price objective on Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the stock an “overweight” rating in a research report on Friday, August 1st. Needham & Company LLC boosted their price objective on Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the stock a “buy” rating in a research report on Thursday, July 31st. Raymond James Financial assumed coverage on Alnylam Pharmaceuticals in a research report on Wednesday, July 30th. They set an “outperform” rating and a $370.00 price objective on the stock. Finally, Evercore ISI boosted their price objective on Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the stock an “outperform” rating in a research report on Thursday, September 11th. Twenty-four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $457.16.

Alnylam Pharmaceuticals Trading Up 0.6%

Shares of ALNY opened at $459.66 on Wednesday. Alnylam Pharmaceuticals has a 52-week low of $205.87 and a 52-week high of $484.21. The business’s fifty day moving average is $451.37 and its 200-day moving average is $345.08. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The firm has a market cap of $60.25 billion, a price-to-earnings ratio of -186.10 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The company had revenue of $773.69 million for the quarter, compared to analyst estimates of $633.54 million. During the same quarter last year, the company posted ($0.13) EPS. The company’s revenue for the quarter was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts anticipate that Alnylam Pharmaceuticals will post -1.7 EPS for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Pushkal Garg sold 3,022 shares of the company’s stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $451.48, for a total value of $1,364,372.56. Following the sale, the executive vice president owned 20,221 shares in the company, valued at approximately $9,129,377.08. The trade was a 13.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Jeffrey V. Poulton sold 3,821 shares of the company’s stock in a transaction dated Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $1,727,283.05. Following the completion of the sale, the executive vice president owned 54,052 shares in the company, valued at $24,434,206.60. This trade represents a 6.60% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 98,144 shares of company stock worth $44,160,261. 1.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

A number of institutional investors have recently made changes to their positions in ALNY. Congress Asset Management Co. bought a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at about $54,173,000. Riversedge Advisors LLC bought a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at about $215,000. Hilltop National Bank bought a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at about $41,000. Fiduciary Alliance LLC bought a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at about $243,000. Finally, Cooper Financial Group bought a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at about $272,000. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.